Mesoblast Ltd

LWB1

Company Profile

  • Business description

    Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

  • Contact

    55 Collins Street
    Level 38
    MelbourneVIC3000
    AUS

    T: +61 396396036

    E: [email protected]

    https://www.mesoblast.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    73

Stocks News & Analysis

stocks

Our view of BHP after June quarter results

Record copper volumes are reported.
stocks

James Hardie transfers of share listing to New York Stock Exchange

The change is a result of the controversial Azek acquisition.
stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,915.5091.30-1.01%
CAC 407,822.670.670.01%
DAX 4024,289.5181.42-0.33%
Dow JONES (US)44,342.19142.30-0.32%
FTSE 1008,992.1219.480.22%
HKSE24,960.64134.980.54%
NASDAQ20,895.6510.010.05%
Nikkei 22539,819.1182.08-0.21%
NZX 50 Index12,950.3669.960.54%
S&P 5006,296.790.57-0.01%
S&P/ASX 2008,664.5092.70-1.06%
SSE Composite Index3,548.3513.870.39%

Market Movers